The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2020 | COMy 2020 highlights: smoldering myeloma, MRD and immunotherapy
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, gives an overview of the topics discussed during the COMy 2020 meeting. The main areas of discussion this year were smoldering myeloma, new drugs approved for multiple myeloma, CAR T-cell therapies and new monoclonal antibodies. The role of MRD in multiple myeloma was also discussed. The meeting this year was very successful with attendees from over 100 countries and thousands of people watching. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
